Examkin

Soru

Zorluk: Çok zorPharmacologic Interventions

A 65-year-old man is evaluated in the surgical intensive care unit for acute right lower extremity pain and swelling. He underwent a coronary artery bypass graft 7 days ago. Since his surgery, he has been receiving subcutaneous unfractionated heparin for deep venous thrombosis (DVT) prophylaxis. Vital signs are stable. Physical examination reveals a swollen, erythematous, and tender right calf. Laboratory studies show a platelet count of 55,000/μL55,000/\mu L, a significant decline from his baseline of 260,000/μL260,000/\mu L immediately post-operation. A compression Doppler ultrasound of the right lower extremity confirms a new occlusive DVT in the popliteal vein. A serotonin release assay is strongly positive. Arrange the following pharmacologic management steps in the correct chronological sequence to optimally treat this patient's acute thrombosis and safely transition him to long-term oral anticoagulation.

  1. 1Discontinue the prophylactic subcutaneous unfractionated heparin
  2. 2Initiate therapeutic anticoagulation with continuous intravenous argatroban
  3. 3Administer the first dose of oral warfarin once the platelet count exceeds 150,000/μL150,000/\mu L
  4. 4Maintain concurrent administration of argatroban and warfarin for at least 5 days
  5. 5Discontinue intravenous argatroban once the international normalized ratio (INR) is therapeutic for 2 consecutive days

Cevap

The correct sequence for managing HIT with thrombosis is: 1) Discontinue all heparin products immediately, 2) Initiate a direct thrombin inhibitor such as argatroban, 3) Wait for platelet count recovery (≥150,000/μL\geq 150,000/\mu L) before starting warfarin, 4) Overlap the direct thrombin inhibitor and warfarin for a minimum of 5 days, and 5) Discontinue the direct thrombin inhibitor only after the INR is therapeutic for 2 consecutive days.
The management of HIT with thrombosis follows a strict, guideline-directed pharmacologic sequence to mitigate the massive prothrombotic risk while safely bridging to outpatient therapy. All heparin must be stopped immediately to remove the immunologic trigger. Because the patient has an active DVT and a hypercoagulable state, an alternative rapidly acting parenteral anticoagulant (argatroban) must be started. The transition to warfarin is notoriously dangerous in HIT; it must be delayed until platelets recover to >150,000/μL>150,000/\mu L to avoid venous limb gangrene caused by rapid Protein C depletion. Finally, a strict minimum 5-day overlap of argatroban and warfarin is required to ensure adequate depletion of Factor II (prothrombin), and argatroban is only stopped after the INR is therapeutic for 2 consecutive days.

Adım Adım Çözüm

1
Stop all heparin products immediately.
Halts further immune complex formation and platelet activation.
Heparin-PF4 antibodies drive the pathophysiology of HIT; removing the antigen stops the primary disease process.
2
Start a direct thrombin inhibitor (e.g., argatroban).
Provides immediate, effective anticoagulation.
The patient has a highly prothrombotic state and an acute DVT, requiring rapid alternate anticoagulation that does not cross-react with HIT antibodies.
3
Monitor platelet counts until recovery (≥150,000/μL\geq 150,000/\mu L).
Ensures the acute hypercoagulable phase of HIT has subsided before transition.
Starting a Vitamin K antagonist during severe thrombocytopenia risks profound hypercoagulability and venous limb gangrene.
4
Initiate warfarin and maintain overlap therapy for ≥5\geq 5 days.
Allows safe and gradual depletion of procoagulant Factor II.
Warfarin rapidly depletes Protein C (an endogenous anticoagulant) long before Factor II (a procoagulant). Overlap prevents warfarin-induced thrombosis.
5
Stop argatroban when INR is therapeutic for 48 hours.
Patient is safely transitioned to long-term oral monotherapy.
Confirms stable, adequate anticoagulation from warfarin alone.

Anahtar Kavram

Pharmacologic sequencing for Heparin-Induced Thrombocytopenia (HIT) with thrombosis
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru